AR044870A1 - TRICYCLED SUCCESSFUL COMPOUND AND ITS USE AS A THERAPEUTIC AGENT FOR THE HYPERACTIVE BLADDER - Google Patents
TRICYCLED SUCCESSFUL COMPOUND AND ITS USE AS A THERAPEUTIC AGENT FOR THE HYPERACTIVE BLADDERInfo
- Publication number
- AR044870A1 AR044870A1 ARP040102183A ARP040102183A AR044870A1 AR 044870 A1 AR044870 A1 AR 044870A1 AR P040102183 A ARP040102183 A AR P040102183A AR P040102183 A ARP040102183 A AR P040102183A AR 044870 A1 AR044870 A1 AR 044870A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- defined above
- same meanings
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Reivindicación 1: Un agente terapéutico para la vejiga hiperactiva asociada a una enfermedad cerebrovascular que incluye, como principio activo, un compuesto tricíclico representado por la fórmula (1), en la que R1 representa un átomo de hidrógeno, halógeno, alquilo inferior sustituido o no sustituido o alcoxi inferior sustituido o no sustituido; X1-X2-X3 representa CR5=CR5-CR7=CR8 (donde R5, R6, R7 y R8, que pueden ser iguales o diferentes, representan cada uno un átomo de hidrógeno, halógeno, hidroxi, nitro, amino, amino monosustituido con alquilo inferior, amino disustituido con alquilo inferior, alquilo inferior sustituido o no sustituido, alcoxi inferior sustituido o no sustituido o alcanoilamino inferior sustituido o no sustituido), N(O)m=CR6-R7=CR8 (donde R6, R7 y R8 tienen cada uno los mismos significados que los definidos anteriormente y m representa 0 ó 1), CR5=CR6-N(O)m=CR8 (donde R5, R6, R8 y m tienen cada uno los mismos significados que los definidos anteriormente), CR5=CR6-CR7=(O) (donde R5, R6, R7 y m tienen cada uno los mismos significados que los definidos anteriormente), CR5=CR6-O (donde R5 y R6 tienen cada uno los mismos significados que los definidos anteriormente), CR5=CR6-S (donde R5 y R6 tienen cada uno los mismos significados que los definidos anteriormente), O-CR7=CR8 (donde R7 y R8 tienen cada uno los mismos significados que los definidos anteriormente), S-CR7=CR8 (donde R7 y R8 tienen cada uno los mismos significados definidos anteriormente) o -O-CR=N (donde R7 tiene el mismo significado que el definido anteriormente); y representa -CH2S-, -CH2-SO-, -CH2SO2-, -CH2O-, -CH=CH-, -(CH2)p- (donde p representa un número entero de 0 a 2), -SCH2-, -SOCH2-, -SO2CH2- o -OCH2-; y R2 representa un átomo de hidrógeno, amino, alquilo inferior sustituido o no sustituido, alquenilo inferior sustituido o no sustituido, alcoxi inferior sustituido o no sustituido, amino monosustituido no alquilo inferior sustituido o no sustituido, amino disustituido con alquilo inferior sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, aralquilamino sustituido o no sustituido, arilamino sustituido o no sustituido o un grupo heterocíclico sustituido o no sustituido o una sal del mismo farmacéuticamente aceptable.Claim 1: A therapeutic agent for the overactive bladder associated with a cerebrovascular disease that includes, as an active principle, a tricyclic compound represented by the formula (1), wherein R1 represents a hydrogen atom, halogen, substituted or non-substituted lower alkyl substituted or substituted or unsubstituted lower alkoxy; X1-X2-X3 represents CR5 = CR5-CR7 = CR8 (where R5, R6, R7 and R8, which may be the same or different, each represent a hydrogen, halogen, hydroxy, nitro, amino, amino monosubstituted alkyl atom lower, amino substituted with lower alkyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy or substituted or unsubstituted lower alkanoylamino), N (O) m = CR6-R7 = CR8 (where R6, R7 and R8 each have one the same meanings as those defined above and m represents 0 or 1), CR5 = CR6-N (O) m = CR8 (where R5, R6, R8 and m each have the same meanings as those defined above), CR5 = CR6- CR7 = (O) (where R5, R6, R7 and m each have the same meanings as defined above), CR5 = CR6-O (where R5 and R6 each have the same meanings as defined above), CR5 = CR6 -S (where R5 and R6 each have the same meanings as defined above), O-CR7 = CR8 (where R7 and R8 each have the same meanings as defined above), S-CR7 = CR8 (where R7 and R8 each have the same meanings defined above) or -O-CR = N (where R7 has the same meaning as defined above); and represents -CH2S-, -CH2-SO-, -CH2SO2-, -CH2O-, -CH = CH-, - (CH2) p- (where p represents an integer from 0 to 2), -SCH2-, - SOCH2-, -SO2CH2- or -OCH2-; and R2 represents a hydrogen atom, amino, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, unsubstituted or unsubstituted lower alkyl amino monosubstituted, substituted or unsubstituted lower alkyl amino , substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino or a substituted or unsubstituted heterocyclic group or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003185476 | 2003-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044870A1 true AR044870A1 (en) | 2005-10-05 |
Family
ID=33549665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102183A AR044870A1 (en) | 2003-06-27 | 2004-06-23 | TRICYCLED SUCCESSFUL COMPOUND AND ITS USE AS A THERAPEUTIC AGENT FOR THE HYPERACTIVE BLADDER |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPWO2005000293A1 (en) |
| AR (1) | AR044870A1 (en) |
| TW (1) | TW200501938A (en) |
| WO (1) | WO2005000293A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200827367A (en) | 2006-10-26 | 2008-07-01 | Kyowa Hakko Kogyo Kk | A therapeutic agent for irritable bowel syndrome |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE201195T1 (en) * | 1995-10-16 | 2001-06-15 | Kyowa Hakko Kogyo Kk | TRICYCLIC COMPOUNDS |
| DE69835877T2 (en) * | 1997-04-15 | 2007-05-16 | Kyowa Hakko Kogyo Co., Ltd. | TRICYCLIC CONNECTIONS |
| US20040106671A1 (en) * | 2001-03-30 | 2004-06-03 | Tsuyoshi Yamagata | Remedies for vesical hyperesthesia |
| WO2002078710A1 (en) * | 2001-03-30 | 2002-10-10 | Kyowa Hakko Kogyo Co., Ltd. | Remedies for vesical hyperactivity |
| CA2442452A1 (en) * | 2001-03-30 | 2002-10-10 | Kyowa Hakko Kogyo Co., Ltd. | Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia |
| JP4104986B2 (en) * | 2001-03-30 | 2008-06-18 | 協和醗酵工業株式会社 | Treatment for bladder irritation symptoms associated with benign prostatic hyperplasia |
-
2004
- 2004-06-23 AR ARP040102183A patent/AR044870A1/en unknown
- 2004-06-23 TW TW093118021A patent/TW200501938A/en unknown
- 2004-06-25 WO PCT/JP2004/009363 patent/WO2005000293A1/en active Application Filing
- 2004-06-25 JP JP2005511115A patent/JPWO2005000293A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005000293A1 (en) | 2005-01-06 |
| JPWO2005000293A1 (en) | 2006-08-03 |
| TW200501938A (en) | 2005-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110400A1 (en) | AMINO-TRIAZOLOPIRIDINE COMPOUNDS AND THEIR USE IN CANCER TREATMENT | |
| AR119651A1 (en) | HETEROCYCLIC AND HETEROARYL COMPOUNDS TO TREAT HUNTINGTON'S DISEASE | |
| CY1122821T1 (en) | 1,3-BENZODIOXOLE DERIVATIVES AS EZE1 AND/OR EZE2 INHIBITORS | |
| DOP2018000187A (en) | DERIVATIVES OF PIRAZOLO [1,5-A] PIRAZIN-4-ILO | |
| AR081058A1 (en) | DERIVATIVES OF ARILMETOXI ISOINDOLINA, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF CANCER. | |
| AR088226A1 (en) | HETEROCICLIC PIPERIDINIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| AR092270A1 (en) | SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
| AR068413A2 (en) | 8-AMINO DERIVATIVES, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THERAPY | |
| CY1112886T1 (en) | Immunosuppressive agent which includes a heterocyclic compound as an active ingredient | |
| CR9459A (en) | BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME | |
| AR054799A1 (en) | OXINDOL DERIVATIVES | |
| AR077695A1 (en) | PIRIMIDINE DERIVATIVES AS INHIBITORS OF FACTOR IXA | |
| CY1119220T1 (en) | Monocyclic Pyridine Derivative | |
| AR072952A1 (en) | 2-IMINO-3-METHYL-PIRROLOPIRIMIDINONA PHENYL-REPLACED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE | |
| AR055592A1 (en) | DERIVATIVES OF 2-AMINO-5-CYCLALKYL-HYDANTOINE AS MODULATORS AND / OR INHIBITORS OF BETA-SECRETASE (BACE) | |
| UY29087A1 (en) | ADAMANTILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USE | |
| AR079226A1 (en) | ESPIROINDOLINONA- PIRROLIDINAS, PREPARATION PROCESSES AND USE OF THE SAME FOR THE TREATMENT AND PROFILAXIS OF CANCER | |
| AR071763A1 (en) | TRISUSTITUTED PIRAZOLS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES OF THE SAME IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | |
| GT200600165A (en) | DIHYDROBENZOFURAN DERIVATIVES AND USES OF THE SAME | |
| ATE553106T1 (en) | HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS | |
| ECSP088129A (en) | NOVEDOUS DERIVATIVE OF HETEROCICLIDEN ACETAMIDA | |
| CL2019002919A1 (en) | Vmat2 inhibitory compounds and related compositions. | |
| AR054790A1 (en) | METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
| AR053342A1 (en) | QUINOLONAS Y NAFTIRIDONAS 7- MAINO ALQUILILDENIL- HETEROCICLICAS | |
| DOP2011000283A (en) | CYCLOPROPIL AMINA DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |